By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: NxThera – Vapor Ablation Therapy for BPH
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Devices > NxThera – Vapor Ablation Therapy for BPH
Medical DevicesMedical InnovationsTechnology

NxThera – Vapor Ablation Therapy for BPH

HerinaAyot
HerinaAyot
Share
2 Min Read
SHARE

NxThera Inc., a St. Paul, Minn.-based privately held medical devices company, has added $12.6 million in Series B financing. American Medical Systems Inc. led the round, and was joined by existing investors Arboretum Ventures, Aberdare Ventures and GDN Holdings. NxThera is developing medical technologies to treat a variety of endourology conditions. The company is developing an innovative and proprietary vapor ablation therapy to treat a variety of endourology conditions, beginning with benign prostatic hyperplasia (BPH). In men, restrictions on the normal flow of urine from the bladder are caused by bladder obstructions, generally the result of BPH or bulbar urethral strictures. Symptoms of BPH include increased urination frequency, sudden urges to urinate, and weak urine flow. More than 70 percent of men over age 60 have some symptoms of BPH. NxThera is developing a novel therapy that delivers vapor directly to the prostate to reduce the tissue volume that causes these obstructions in a simple, office-based procedure designed to take only minutes, with minimal discomfort, and resulting in rapid and significant improvements in urine flow. BPH afflicts more than 32 million men in the United States. The company plans to use this capital to initiate a pivotal BPH clinical study outside of the United States and to obtain CE mark approval needed to support the introduction of its product in the European Economic Area. NxThera also has begun the process of seeking appropriate FDA approvals to undertake a second arm of the BPH clinical study in the U.S. Some other companies making advancements in the field of Urology include, but are not limited to HealthTronics and Urologix.

TAGGED:BPHmedical innovationsNxThera
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Nurse Scheduling Software
Evaluating 7 Best Nurse Scheduling Software
Nursing Technology
October 28, 2025
contamination
Batch Failures And The Hidden Costs Of Contamination
Health Infographics
October 21, 2025
Medication Management For Seniors
Simplifying Medication Management For Seniors
Infographics Senior Care
October 21, 2025
Guide To Pursuing a Career in Nursing as a Foreigner in the USA
Collaboration Is the Prescription for Better Patient Care
Health
October 20, 2025

You Might also Like

Emerging Diabetes Treatment Options

February 23, 2011
Dr. Michael James McCoy
Policy & LawTechnology

5 Questions with Michael James McCoy

March 3, 2015
healthcare tech
BusinesseHealthHealth ReformMedical InnovationsMobile HealthPublic HealthTechnology

Healthcare Companies Are Now Technology Companies?

May 21, 2014

RealBio – Revolutionary Cell Culture Technology

March 16, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?